EP1920418A2 — Implantable zero-wire communications system
Assigned to Proteus Digital Health Inc · Expires 2008-05-14 · 18y expired
What this patent protects
The present invention shows an implantable system that communicates wirelessly with each other using a unique format that enables device configurations and applications heretofore not possible. Sensors (205, 206, 208,204) are located on a body (200) communicate with each other an…
USPTO Abstract
The present invention shows an implantable system that communicates wirelessly with each other using a unique format that enables device configurations and applications heretofore not possible. Sensors (205, 206, 208,204) are located on a body (200) communicate with each other and with a data collector (106) by exchanging information using quasi-electrostatic signal transmission in a long wavelength/low frequency electromagnetic band, with the patient's body acting as a conductive medium
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.